#MappBio - Twitter Hashtag

almost 2 years ago

Thrilled to see the US sending #vaccines and #therapeutics to #Rwanda to fight #Marburg: - #Sabin chAd-3 vaccine (Phase 2 trials in #Uganda & #Kenya) - #MappBio’s MBP-091 mAb doses These treatments are crucial, but we also need to optimize medical care, enhance prevention/control measures, and engage at-risk communities to prevent further spread.

Helen Branswell 🇨🇦

@HelenBranswell

almost 2 years ago

The US is sending 700 doses of an experimental #Marburg vaccine & an unspecified number of doses of a monoclonal antibody treatment to Rwanda to help with its still-growing outbreak. The case count is up to 41 cases & 12 deaths. https://t.co/QblwMkT5Pt

8

202

85

24

69K

2

23

8

3

5K

Bob Cross @RobertWCross1

over 2 years ago

Another great day for science! Our recent paper in STM published today also made the cover! Great work with a great team! Overjoyed to add yet another treatment option for Nipah virus! #MAPPBio & #USHUS @UTMBPresident @utmbnews https://t.co/eW8NATi7M8

RobertWCross1's tweet photo. Another great day for science! Our recent paper in STM published today also made the cover! Great work with a great team! Overjoyed to add yet another treatment option for Nipah virus! #MAPPBio & #USHUS @UTMBPresident @utmbnews https://t.co/eW8NATi7M8 https://t.co/9j6TJVjLYu

5

35

9

2

4K

Ha Van Dang @HaVanDang2712

about 5 years ago

Another one! Our paper characterizing novel potent anti-Henipavirus antibodies and antibody cocktails is out in NSMB! Could not have done this without amazing collaborators from USU, UTMB, Mayo Clinic and #MappBio @RobertWCross1 @LarryZeitlin @ZABornholdt @choxybus @veeslerlab

The Veesler Lab @veeslerlab

about 5 years ago

Our latest work on antibodies targeting the fusion (F) glycoprotein of Nipah virus and Hendra virus is out! Work led by @HaVanDang2712 in collaboration with the groups of Chris Broder Thomas Geisbert @LarryZeitlin @RobertWCross1 @choxybus 1/5 https://t.co/qwKbuCwQ3V

2

46

6

3

0

13

3

0

Abhishek Prasad @polylepis82

almost 6 years ago

Great to see this paper out today modeling a "worst-case" scenario where a recent #rVSV-EBOV vaccinee is exposed prior to development of immunity, and then treated with mAb. See what we found! Really proud of our team here @utmbhealth and our collaborators at #MappBio, @NIH @MSF

1

0

Jeremy Farrar @JeremyFarrar

almost 7 years ago

Amid most complex #Ebola epidemic-very important. Enormous respect all involved & hugely important -patients,families,INRB,#DRC,@MinSanteRDC, @ALIMA_ORG,@MSF,@WHO @NIH @NIAIDNews @NIHDirector #MappBio,@GileadSciences @Regeneron #RidgebackBiotherapeutics https://t.co/RXBciFuXKD

0

11

4

0

Helen Branswell 🇨🇦

@HelenBranswell

over 7 years ago

2. For anyone curious about the breakdown of how many #Ebola patients got which drug, here goes: mAb 114, 47 patients; #Regeneron's mAb, 43; #Gilead's Remdesivir, 34; #MappBio's ZMapp, 15.

0

5

1

0

McHeyzer-Williams @mmw_lmw

over 8 years ago

#EbolaV | Antibodies from Human Survivor: defines protective sites | Dye Chandran Bornholdt #MAPPBio @CellCellPress https://t.co/sxTo2qEZW2 | #YearBook2017